US EditionPublished • loading... • Updated
Coreline Soft and INFINITT North America Deliver True "Zero-Click" AI Workflow to U.S. Radiology Practices
Coreline's AVIEW platform automates calcium scoring and lung nodule detection, improving efficiency and clinical sensitivity in U.S. radiology groups processing over 6,000 cases quarterly.
- Coreline Soft and INFINITT North America reported on Feb. 14, 2026, a zero-click AI workflow now live in U.S. radiology practices from Phillipsburg, N.J., and Seoul.
- Driven by demand for operational infrastructure, Coreline introduced the INFINITT Integration Suite to support rapid deployment and CPT reimbursement, responding to the market shift.
- By embedding AVIEW platform inside INFINITT PACS, the integration automates coronary artery calcium scoring, enhances lung nodule detection, and removes manual steps so radiologists can focus on patient care.
- High-Volume radiology groups processing over 6,000 cases per quarter reported improved clinical sensitivity and revenue growth, while ImageCare Radiology rolled out the system in one month with immediate benefits.
- At STR 2026, Coreline will showcase AVIEW LCS and related modules that automate lung cancer screening workflows, offering demos to attendees.
Insights by Ground AI
22 Articles
22 Articles
Coreline Soft and INFINITT North America Deliver True “Zero-Click” AI Workflow to U.S. Radiology Practices
Seamless AI Integration Drives Efficiency, Accuracy, and Revenue for Radiology Groups PHILLIPSBURG, N.J. and SEOUL, South Korea, Feb. 14, 2026 /PRNewswire/ — As the global medical AI market shifts from simple algorithm accuracy to integrated operational infrastructure, Coreline Soft has teamed up with INFINITT North America to bridge the gap between advanced technology and daily clinical practice. The partnership has successfully deployed a full…
Coverage Details
Total News Sources22
Leaning Left5Leaning Right4Center6Last UpdatedBias Distribution40% Center
Bias Distribution
- 40% of the sources are Center
40% Center
L 33%
C 40%
R 27%
Factuality
To view factuality data please Upgrade to Premium
